Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant
cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg
bodyweight i.v. in 4-weekly intervals and 162mg weekly s.c., respectively). In both trials
glucocorticoids (GC) were initially administrated at medium to high doses with subsequent
rapid reduction and discontinuation over 24 weeks. In case of relapse, GC doses were
re-increased.
The results of both studies suggest that GC could be reduced more rapidly. This would further
reduce GC-induced adverse effects.
Thus, the investigators propose to perform an open label single arm study to assess the
efficacy of ultra-short co-medication with GC, using Simon's minimax two-stage design.